Live
- GAIL clocks net profit of Rs 2,672 crore in Q2
- Sr Men's National Hockey: Delhi, Karnataka, Bengal, A.P. win group matches on Day 2
- ‘Nation is proud of you’: West Bengal Guv to GRSE on laying keels of two NGOPVS
- Kirttane, Kapadia bag golden double as India wins 14 medals in Asia Pickleball Games
- Gurugram: 11 projects of GMDA worth Rs 249.77 crores approved
- Akali Dal stages statewide protests over ‘tardy’ paddy procurement in Punjab
- Firing on Nandan Kanan Express in Odisha, probe launched
- Indian Army Seizes Massive Cache Of Arms And Ammunition In Manipur Amid Ongoing Violence
- Polling Stations Open Across Eastern And Central US As Voters Head To The Ballots In Historic Election
- Hyatt set to expand brand presence in Nepal with hyatt regency lumbini
AstraZeneca Covid vaccine can be 90% effective
AstraZeneca Covid vaccine can be 90% effective
AstraZeneca said on Monday that its vaccine for the novel coronavirus could be around 90% effective without any serious side effects, said the drugmaker unveiling positive interim data.
New Delhi: AstraZeneca said on Monday that its vaccine for the novel coronavirus could be around 90% effective without any serious side effects, said the drugmaker unveiling positive interim data.
The vaccine developed by Oxford University was 90% effective in preventing Covid-19 when it was administered as a half dose followed by a full dose at least one month apart, according to data from the late-stage trials in Britain and Brazil.
Another dosing regimen showed 62% efficacy when given as two full doses at least one month apart and the combined analysis from both dosing regimens resulted in an average efficacy of 70%. All results were statistically significant. No serious safety events related to the vaccine have been confirmed and it was well tolerated across both dosing regimens, it said.
"This vaccine's efficacy and safety confirm that it will be highly effective against COVID-19 and will have an immediate impact on this public health emergency," Pascal Soriot, Astra's chief executive, said in a statement.
The British drugmaker's preliminary trial results mark a fresh breakthrough in the fight against a pandemic that has killed nearly 1.4 million people and roiled the global economy.
